Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant and Binimetinib in HR+ Metastatic Breast Cancer With NF1 Alterations (ComboMATCH)
NCT05554354Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Sep 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of binimetinib in breast cancer, sponsored by National Cancer Institute. Started Sep 2024; status: terminated.
02
Drugs
binimetinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05554354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05554354.